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Background: There has been increasing emphasis on evidence-based approaches to improve patient outcomes
through rigorous, standardised and well-validated approaches. Clinical guidelines drive this process and are largely
developed based on the findings of systematic reviews (SRs). This paper presents a discussion of the SR process in
providing decisive information to shape and guide clinical practice, using a purpose-built review database: the
Cochrane reviews; and focussing on a highly prevalent medical condition: hypertension.
Methods: We searched the Cochrane database and identified 25 relevant SRs incorporating 443 clinical trials.
Reviews with the terms ‘blood pressure’ or ‘hypertension’ in the title were included. Once selected for inclusion, the
abstracts were assessed independently by two authors for their capacity to inform and influence clinical decision-
making. The inclusions were independently audited by a third author.
Results: Of the 25 SRs that formed the sample, 12 provided conclusive findings to inform a particular treatment
pathway. The evidence-based approaches offer the promise of assisting clinical decision-making through clarity, but
in the case of management of blood pressure, half of the SRs in our sample highlight gaps in evidence and
methodological limitations. Thirteen reviews were inconclusive, and eight, including four of the 12 conclusive SRs,
noted the lack of adequate reporting of potential adverse effects or incidence of harm.
Conclusions: These findings emphasise the importance of distillation, interpretation and synthesis of information to
assist clinicians. This study questions the utility of evidence-based approaches as a uni-dimensional approach to
improving clinical care and underscores the importance of standardised approaches to include adverse events,
incidence of harm, patient’s needs and preferences and clinician’s expertise and discretion.
Keywords: Systematic review, Research-in-practice, Research implementation, Translational research, Evidence-based
practice, Clinical decision-makingBackground
Much has been written about evidence-based medicine
(EBM) and its potential to inform practice. The termin-
ology surrounding the aggregation of evidence in a sys-
tematic way implies that there is a practical import to this
work, and the terms “evidence-based practice” (EBP) and
“evidence-based approaches” (EBA) have arisen from this
concept. The EBA are among the most significant con-
temporary ways of conceptualising health care, both the-
oretically and practically [1], and are viewed by advocates
as the favoured means of integrating research findings into
clinical practice [2].* Correspondence: debra.jackson@uts.edu.au
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reproduction in any medium, provided the orDespite the appeal of EBA, and the widespread recog-
nition of this approach in driving care, they present a
number of challenges, and there has been a steady
undercurrent of concern about their pervasive accept-
ance and promotion. Debate has focussed on several key
factors, including the nature of evidence, particularly the
privileging of some forms of evidence and the marginalising
and devaluing of others [2-5]. Concerns that the domin-
ation of the EBA has (and will continue to) foster ‘a very
rational, traditional, biomedical approach to research use/
evidence-based practice’ [5] forms a crucial plank of the
critique. Additional major critiques of EBA highlight
concerns that they do not meet the challenges of rare
diseases or unusual presentations, and may foster a “cook-
book” approach to practice [6]. An additional view is thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physician relationships; including the charge that they cre-
ate or contribute to an environment of paternalism and
reductionism that can render patient preference and ex-
perience invisible and irrelevant [1-3,7]. According to this
critique, EBA can foster a therapeutic milieu in which
patients are positioned as passive recipients in the medical
encounter [1], and clinicians are limited in their ability to
draw on intuitive and other forms of knowledge [7].
Notwithstanding the theoretical critique however, the
aim of EBA is to facilitate the integration of the best
available research evidence into practice by transparently
assimilating information and aggregating data in ways
that can help guide clinical decision-making [6]. Indeed,
the EBA are attractive because they promote the idea of
research-in-practice, yet present an alternative to each
clinician locating, reading and assimilating the plethora
of contemporary research literature on any clinical issue
[6]. However, we argue that in some areas, even where a
substantial body of literature exists, there is a lack of evi-
dence to demonstrate that the EBA in fact provide the
information necessary to effectively guide clinicians.Purpose of this paper
The purpose of this paper is to explore the efficacy of
the systematic review (SR) process in providing de-
cisive information to shape and guide clinical practice.
To do this we examined SRs on the management of
blood pressure. We chose this because hypertension is
a well-researched, common and persistent condition
with a significant effect on health outcomes [8]. The
Cochrane reviews on reducing blood pressure became
the lens through which we explored the efficacy of the
SR process in providing contemporary and clear infor-
mation upon which clinical practice decisions could be
made.Methods
Independent manual searches of the reviews published
on the Cochrane Database of Systematic Reviews (http://
www.cochrane.org/cochrane-reviews) on 1/12/11 were
undertaken to search for SRs on interventions to lower
blood pressure. Reviews with the terms ‘blood pressure’
or ‘hypertension’ in the title were included. Once se-
lected for inclusion, the abstracts were assessed inde-
pendently by two authors. SRs were excluded if they
pertained to blood pressure targets, pulmonary hyper-
tension, hypertensive emergencies, acute cardiac events,
gestational, postpartum, infant, neonatal and child hyper-
tension. Furthermore, SRs were also excluded if the
details of the number of clinical trials were not provided,
and if the SR did not include any completed studies.
Inclusions were independently audited by a third author.Results
Twenty-five SRs representing a combined total of 443
clinical trials were identified (see Table 1). Of these SRs,
the majority reported pharmaceutical-based interven-
tions. Salt intake, weight-reducing diets, timing of medi-
cation and relaxation therapies were each the subject of
a single SR. Twelve SRs made conclusive assertions, that
is, they used language that denoted a degree of certainty.
The remaining SRs (n = 13) were inconclusive (see
Table 2).
Discussion
In eight SRs, including four of the 12 SRs that were
considered to be conclusive, the lack of adequate re-
porting of potential adverse effects or incidence of harm
was specifically noted (see Table 2). These factors would
exert an influence on clinicians and on the confidence
they can have in selecting specific treatments as a result
of any SR. There has long been concern that clinicians
can be slow to take up research findings into their prac-
tice, with a common focus being on accessibility of
current information and the most efficacious means of
dissemination [9,10]. However, findings from this exer-
cise suggest there needs to be more of an onus on
researchers to produce findings that are able to inform
practice in a more useful way.
Attention is also drawn to the use and effect of extrane-
ous words such as ‘appears to’ in reaching conclusions. It
could be seen that use of this ambiguous language means
that results are being presented cautiously but it could
also have the effect of creating doubt or suggest an unwill-
ingness or inability to have an opinion either way. Lan-
guage is a problematic area in research [11], but much of
the scrutiny about language and how it is used to present
research focuses on the use of jargon or exclusionary lan-
guage. When considering the use of ambiguous language -
language which creates doubt and jeopardises meaning,
questions about the nature of language and how it is used
arise. How essential is the word (that causes the doubt) to
the significance and meaning of the message? If we took
those words out, would we have clear cut messages? If the
words create the doubt, what is the point in having this
process? If results cannot be interpreted with confidence,
how can conclusions be reached through the SR process?
The inconclusive nature of several SRs raises a number
of additional issues for consideration. The point of EBA
as a systematic transparent process is to allow for the
aggregation of data so that statistical significance may be
achieved. In our sample, it was noted that some of the
included studies were unreliable because of potential
bias, questionable rigour or other factors which meant
studies were deemed to be poor quality. The EBA have
been the catalyst for the development of a ranking sys-
tem, known as the hierarchy of evidence [12,13].
Table 1 Included systematic reviews
Title Date Authors No oftrials
Creatine and creatine analogues in hypertension and cardiovascular disease 2011 Horjus, et al. 11
Evening versus morning dosing regimen drug therapy for hypertension 2011 Zhao P, et al. 21




Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension 2010 Chen, et al. 20
Spironolactone for hypertension 2010 Batterink, et al. 5
Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for
primary hypertension
2010 Heran, et al. 6
Pharmacotherapy for hypertension in the elderly 2010 Musini, et al. 15
Blood pressure lowering efficacy of alpha blockers for primary hypertension 2009 Heran, et al. 10
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension 2009 Heran, et al. 92
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension 2009 Heran, et al. 46
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension 2009 Ho, et al. 3
Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension 2009 Chen, et al. 56
Blood pressure lowering efficacy of loop diuretics for primary hypertension 2009 Musini, et al. 9










Methyldopa for primary hypertension 2009 Mah, et al. 12
Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2009 Musini, et al. 6




Relaxation therapies for the management of primary hypertension in adults 2009 Dickinson, et al. 25
Potassium supplementation for the management of primary hypertension in adults 2009 Dickinson, et al. 5
Magnesium supplementation for the management of primary hypertension in adults 2009 Dickinson, et al. 12
Calcium supplementation for the management of primary hypertension in adults 2009 Dickinson, et al. 13




Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in
adults
2009 Beyer, et al. 3
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will be able to draw on EBA, and we concur with this,
even where findings are inclusive. Furthermore, it is
recognised and understood that information drawn from
EBA is only one of a number of factors that inform clin-
ical judgement. But, clearly there is a need to provide
some guidance about interventions that may never be
able to be proven in the current evidentiary way. At the
moment this is left to institutions through mechanisms
such as clinical pathways, regulators such as the Na-
tional Institute of Clinical Excellence (NICE), and the
National Health and Medical Research Council. Someprogress is being made as groups both in the community
and within organisations are trying to develop method-
ologies to assist this process, such as through modelling.
Systematic reviews are only as good as the sum of the
parts. Strategies such as standardised reporting of clin-
ical trials through CONSORT methods offer some pro-
mise in increasing the rigour and usefulness of research
(http://www.consort-statement.org/). The recognition of
complex interventions in clinical care is another import-
ant consideration [14]. In this instance some interven-
tions may have high internal validity, yet less external
validity.
Table 2 Authors’ conclusions
Authors Comments from author’s conclusions (all comments taken directly from author conclusions as appeared on CochraneDatabase of Systematic Reviews 1/12/11)
Horjus, et al.
This review found inconclusive evidence to decide on the use of creatine analogues in clinical practice.
The effect on death and the size of myocardial infarction and the heart function were unclear.
Given the small sample size of the discussed trials and the heterogeneity of the population included in these reports, larger clinical
studies are needed to confirm these observations.
Zhao P, et al.
In terms of BP lowering efficacy, for 24-hour SBP and DBP, the data suggests that better blood pressure control was achieved with
bedtime dosing than morning administration of antihypertensive medication, the clinical significance of which is not known.
Siebenhofer,
et al.
The magnitude of the effects are uncertain as a result of the small number of patients and studies that could be included in the
analyses.
It is not known whether weight loss reduces mortality and morbidity.
No useful information on adverse effects was reported in the relevant trials.
In conclusion, there is no evidence for effects of weight loss diets on death or long-term complications and adverse events.
In addition, results on blood pressure and body weight could be considered uncertain, because not all studies were included in the
analyses.
Chen, et al.
The different effect on diastolic BP means that beta-blockers have little or no effect on pulse pressure whereas thiazides cause a
significant dose-related decrease in pulse pressure.
Batterink, et al.
From the limited available evidence, spironolactone appears to lower blood pressure compared to placebo to a similar degree in
patients with primary (essential) hypertension when doses of 100-500 mg/day are given.
A dose of 25 mg/day did not statistically significantly reduce systolic or diastolic blood pressure, compared to placebo.
Given the lack of a dose-response, coupled with a possible increased risk in adverse events with higher doses, doses of 25 to 100
mg/day are reasonable.There is no evidence of the effect of spironolactone on clinical outcomes in hypertensive patients.
Heran, et al.
ENaC blockers do not have a statistically or clinically significant BP lowering effect at low doses but trials at higher doses are not
available.
The review did not provide a good estimate of the incidence of harms associated with ENaC blockers
Wiysonge, et al.
Thirteen RCTs were found and these trials suggested that first-line beta-blockers for elevated blood pressure were not as good at
decreasing mortality and morbidity as other classes of drugs: thiazides, calcium channel blockers, and renin angiotensin system
inhibitors.
Heran, et al.
The BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of -8/-5 mmHg is likely
an overestimate.
There are no clinically meaningful BP lowering differences between different alpha blockers.
The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short
duration of the trials and the lack of reporting of adverse effects in many of the trials.
Heran, et al.
There are no clinically meaningful BP lowering differences between different ACE inhibitors.
The BP lowering effect of ACE inhibitors is modest.
The review did not provide a good estimate of the incidence of harms associated with ACE inhibitors because of the short duration
of the trials and the lack of reporting of adverse effects in many of the trials
Heran, et al.
The evidence from this review suggests that there are no clinically meaningful BP lowering differences between available ARBs.
The BP lowering effect of ARBs is modest and similar to ACE inhibitors as a class.
The review did not provide a good estimate of the incidence of harms associated with ARBs because of the short duration of the
trials and the lack of reporting of adverse effects in many of the trials
Ho, et al.
Due to the possible unreliability of some of the included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in
the long-term management of primary hypertension
Chen, et al.
Thiazides when given as a second-line drug have a dose related effect to lower blood pressure that is similar to when they are
added as a first-line drug. This means that the BP lowering effect of thiazides is additive.
Because of the short duration of the trials and lack of reporting of adverse events, this review does not provide a good estimate of
the incidence of adverse effects of diuretics given as a second-line drug
Musini, et al.
Based on the limited number of published RCTs, the SBP/DBP lowering effect of loop diuretics is modest . . . and is likely an overestimate
due to the high risk of bias in the included studies.
There is no clinically meaningful BP lowering differences between different drugs within the loop diuretic class.
The dose ranging effects of loop diuretics could not be evaluated.
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Table 2 Authors’ conclusions (Continued)
The review did not provide a good estimate of the incidence of harms associated because of the short duration of the trials and
the lack of reporting of adverse effects in many of the trials.
Shamon &
Perez
Reserpine is effective in reducing SBP roughly to the same degree as other first-line antihypertensive drugs.
However, we could not make definite conclusions regarding the dose-response pattern because of the small number of included trials.
More RCTs are needed to assess the effects of reserpine on blood pressure and to determine the dose-related safety profile before
the role of this drug in the treatment of primary hypertension can be established
McGuinness,
et al.
There is no convincing evidence from the trials identified that blood pressure lowering in late-life prevents the development of
dementia or cognitive impairment in hypertensive patients with no apparent prior cerebrovascular disease.
There were significant problems identified with analysing the data, however, due to the number of patients lost to follow-up and the
number of placebo patients who received active treatment. This introduced bias.
More robust results may be obtained by conducting a meta-analysis using individual patient data.
Mah, et al.
Methyldopa lowers blood pressure to varying degrees compared to placebo for patients with primary hypertension.
Its effect on clinical outcomes, however, remains uncertain.
Overall reporting of adverse effects was poor so no conclusions can be drawn about the adverse effect profile.
This meta-analysis shows that methyldopa reduces systolic/diastolic blood pressure by approximately 13/8 mmHg compared to
placebo.
Musini, et al.
Aliskiren has a dose-related blood pressure lowering effect better than placebo.
This effect is similar to that determined for ACE inhibitors and ARBs
Wright &
Musini
First-line low-dose thiazides reduce all morbidity and mortality outcomes.
First-line ACE inhibitors and calcium channel blockers may be similarly effective but the evidence is less robust.
Dickinson, et al.
In view of the poor quality of included trials and unexplained variation between trials, the evidence in favour of causal association
between relaxation and blood pressure reduction is weak.
It was difficult to disentangle their effects, especially as many trials used a combination of methods
some of the reduction in blood pressure was almost certainly due to aspects of treatment that were not related to relaxation, such as
frequent contact with professionals who were trying to help.
Dickinson, et al.
Due to small number of participants in the two high quality trials, the short duration of follow-up, and the unexplained heterogeneity
between trials, the evidence about the effect of potassium supplementation on blood pressure is not conclusive.
Further high quality RCTs of longer duration are required to clarify whether potassium supplementation can reduce blood pressure
and improve health outcomes.
Most included trials were of poor quality, so their results may not be reliable.
The trials were not long enough or large enough to measure whether potassium supplements reduce the risk of death, heart attack or
stroke, which may be caused by high blood pressure.
This review does not confirm whether potassium supplements can lower high blood pressure and therefore does not recommend
them for treating hypertension.
More trials enrolling a large number of participants with long periods of follow-up are necessary to know whether or not potassium
supplements can lower high blood pressure.
Dickinson, et al.
In view of the poor quality of included trials and the heterogeneity between trials, the evidence in favour of a causal association between
magnesium supplementation and blood pressure reduction is weak and is probably due to bias.
This is because poor quality studies generally tend to over-estimate the effects of treatment.
Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of magnesium
supplementation on blood pressure and cardiovascular outcomes.
Dickinson, et al.
Due to poor quality of included trials and heterogeneity between trials, the evidence in favour of causal association between calcium
supplementation and blood pressure reduction is weak and is probably due to bias.
This is because poor quality studies generally tend to over-estimate the effects of treatment.
Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of calcium
supplementation on blood pressure and cardiovascular outcomes.
Musini, et al.
Treating healthy persons (60 years or older) with moderate to severe systolic and/or diastolic hypertension reduces all cause
mortality and cardiovascular morbidity and mortality. The decrease in all cause mortality was limited to persons 60 to 80 years of
age.
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Beyer, et al.
None of the trials were of high quality, so their results may not be reliable.
We found no robust evidence that supplements of any combination of potassium, magnesium or calcium reduce mortality, morbidity or
BP in adults.
More trials are needed to investigate whether the combination of potassium & magnesium is effective.
He &
MacGregor
Our meta-analysis demonstrates that a modest reduction in salt intake for a duration of 4 or more weeks has a significant and, from
a population viewpoint, important effect on blood pressure.
These results support other evidence suggesting that a modest and long-term reduction in population salt intake could reduce
strokes, heart attacks, and heart failure.
Key
Italicised text Inconclusive result.
Underlined text No/poor reporting of adverse effects or incidences of harm.
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Though the EBA offer the promise of direction through
clarity, in the case of reducing blood pressure, and des-
pite the enormous amount of research that has been
undertaken, the clarity offers little direction for the fu-
ture, in the main, aggregating the past. Rather, it
highlights evidentiary gaps and weaknesses. Indeed, one
of the real values of the SR process is that it summarises
what we know, which is potentially not what we need to
know – what should I do for the 85 year old women sit-
ting in my clinic?
Our results highlight a potential lack of efficacy of the
SR process in driving future practice, which may leave fu-
ture practice potentially open to other, less evidence-based
directions. Krumholz [15] has recently highlighted the im-
perative of method in generating clinical research that is
able to effectively inform practice. Through this exercise
we have shown that even in areas where it might be
thought to be strong, such as in the aggregation of drug
trials, the results were often not clear and therefore their
utility for informing practice is compromised. This may be
a factor of the analytic techniques that are used. To be
useful in clinical practice, there is a need to develop more
robust methodologies and to ensure that research pro-
cesses are well described and sufficiently transparent to
allow data aggregation to occur with confidence.
Furthermore, it was noted that in some SRs inadequate
information about prevalence of harm, complications and
potential adverse effects were presented. In order that
results are as clinically meaningful and useful as possible,
there is a need to ensure reporting of presence or absence
of these factors.
This review also emphasises the need for expertise and
interpretation when developing clinical practice guidelines,
particularly in the absence of robust Level 1 evidence and
differences in clinical trial populations and patient groups.
Indeed, it is certainly important to identify where the evi-
dence does not support a particular line of practice. We
argue that the corollary is not disproven by this approach,
that is, practice may be improved by a particular interven-
tion despite the null hypothesis, but the evidence isn’tstrong enough in a normative way. There are many pos-
sible reasons why the level of evidence to support EBA in
practice will not always be strong enough to inform prac-
tice. Assessing change in practice is difficult and robust
methodologies have yet to be derived; the process is long-
term and it will take some time for robust evidence to
emerge; and, the evidence provided to support clinical
decision-making may no longer be useful in practical
settings. Based upon this review, data from SRs are only
one part of the picture. Using systematic guideline develop-
ment processes such as in ADAPTE framework are an im-
portant part of this process (http://www.adapte.org/www/).
Clearly there is a desire for contemporary and rigorous
information upon which clinical treatment can be guided
and individual clinical decisions made. The demand for
this is evidenced in Cochrane’s own usage data, which
states that “every day someone, somewhere searches The
Cochrane Library every second, reads an abstract every
two seconds and downloads a full-text article every three
seconds” (www.cochrane.org)(: accessed 16/1/12).
Initially, the EBA have been viewed as a way of incorp-
orating research into practice. The EBA does not always
have high utility and reference for consistently assisting
clinicians, particularly in groups not included in clinical
trials. While the use of a single health issue may be
viewed as a limitation of this paper; in using this com-
mon health issue – blood pressure management - as a
lens, we have raised questions about whether SRs as the
core of clinical guideline development can reliably influ-
ence practice in an interventional way, and about the
strength of evidence that is available to inform clinical
practice in some key areas.
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